Emory University in Atlanta will begin enrolling healthy adult volunteers ages 18 to 55 years in a Phase 1 clinical trial of an investigational vaccine designed to prevent coronavirus disease 2019 (COVID-19).
NIAID
Ebola Therapeutics Trial in DRC shows Favorable Results
An independent monitoring board has recommends the early termination of Ebola Therapeutics Trial in DRC Because of Favorable Results with Two of Four Candidates.
In rare cases, immune system fails despite HIV suppression
Antiretroviral therapy (ART) is usually very effective at suppressing HIV in the body, allowing a person’s immune system to recover by preventing the virus from destroying CD4+ T cells(link is external).
Tuberculosis Diagnosis in People with HIV Increases Risk of Death Within 10 Years
Among people with HIV in Latin America, those diagnosed with tuberculosis (TB) at an initial clinic visit were about twice as likely to die within 10 years as people not initially diagnosed with TB, according to findings from a large observational study.
With Antibody-Drug Combination, NIAID Scientists Improve Outcomes of Bone Marrow Transplants in Mice
In a new paper published February 6 in Nature Communications, researchers from NIAID and Harvard University describe a way to better prepare a recipient to tolerate bone marrow donation, using an antibody-drug conjugate that combines a cell-targeting antibody with a cell toxin, which the antibody carries as cargo.
Meeting the challenge of engaging men in HIV prevention and treatment
A new commentary from National Institutes of Health scientists asserts that engaging men in HIV prevention and care is essential to the goal of ending the HIV pandemic.
Clinical trial of investigational Ebola treatments begins in the Democratic Republic of the Congo
An international research team has begun patient enrollment in a clinical trial testing multiple investigational Ebola therapies in the Democratic Republic of the Congo (DRC).
Specimen-news.com 